Compare American Homes 4 Rent Class A (AMH) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Homes 4 Rent Class A vs BridgeBio Pharma Inc — how do they compare? American Homes 4 Rent Class A trades at $33.92 (market cap $12.28B), while BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap, and American Homes 4 Rent Class A pays a 3.87% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| AMH | BBIO | |
|---|---|---|
Market Cap | $12.28B | $16.61B |
Sector | Real Estate | Health |
52-Week High | $35.82 | $90.17 |
52-Week Low | $27.38 | $47.29 |
Enterprise Value | $17.35B | $18.16B |
Dividend Yield | 3.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMH (American Homes 4 Rent) trades at $34.63, up 0.23% with strong technical momentum and bullish moving averages. The REIT demonstrates robust fundamentals with consistent revenue growth from $1.5B in 2022 to $1.85B in 2025, net income margin expansion to 25.53%, and three consecutive quarterly EPS beats. Recent Q2 2026 results exceeded FFO estimates, prompting raised full-year guidance. Institutional activity shows mixed positioning while analyst consensus remains positive with a $36.45 price target.
AMH presents a compelling opportunity with strong operational execution in the single-family rental market, though investors face risks from regulatory changes affecting institutional home ownership and elevated debt levels. The stock's current valuation at 27.48 P/E appears reasonable given growth trajectory, but monitoring legislative impacts and interest rate sensitivity remains crucial for sustained performance.
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Homes 4 Rent Class A
American Homes 4 Rent is a real estate investment trust primarily focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's largest geographical markets include Dallas, Texas
Read more on AMH →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
